Shame about the strategy

29 Jun 2004 By Robert Cyran

Such a deal would bulk up the German conglomerate’s OTC drugs business and reduce combined costs. But the deal must not distract from bigger strategic issues. The company needs to be broken up.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)